Study identifier | Study design | Inclusion criteria/study groups | Number of patients | Median age (year) | Gender (male: female) | Cyclophosphamide dose | Acute GVHD percentage | Infection percentage | Response rate (%) |
---|---|---|---|---|---|---|---|---|---|
K. Hattori et al. [11] | Case report | HC after allogeneic SCT in children | 2 | 7 | 2:00 | 60 mg/kg/day for 2 days, 50 mg/kg/day for 4 days | 0 | 0 | 100 |
S. Cesaro et al. [12] | Cross sectional | HC in pediatric patients after SCT | 38 | 10.8 | 4:01 | Not disclosed | 20 | 71 | 84 |
M. Payandeh et al. [13] | Case report | HC after allogeneic SCT in AML patient | 1 | 40 | 1:00 | Not disclosed | 100 | 0 | 100 |